novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Vascular protection. New concept, new opportunity for prevention – Harald Darius

1 Agosto 2018

Resumo da Apresentação

Apresentação

Tags:
Harald Darius

Reflections about the cardiovascular risk after 12 months myocardial infarction - Christian Hamm

1 Agosto 2018
0

APP MIC - Monitor de Insuficiência Cardíaca - Catarina Ruivo

1 Agosto 2018
0

-->